|
CN104136037B
(zh)
*
|
2012-01-17 |
2018-02-23 |
小利兰·斯坦福大学托管委员会 |
高亲和力SIRP‑α试剂
|
|
HRP20191500T1
(hr)
|
2012-02-06 |
2019-11-29 |
Inhibrx Inc |
Protutijela protiv cd47 i postupci njihove upotrebe
|
|
DK2931752T3
(da)
*
|
2012-12-17 |
2019-11-18 |
Trillium Therapeutics Inc |
Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
|
|
AU2014238105B2
(en)
|
2013-03-15 |
2018-11-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for achieving therapeutically effective doses of anti-CD47 agents
|
|
ES2898627T3
(es)
*
|
2013-04-29 |
2022-03-08 |
Univ Leland Stanford Junior |
Uso de agentes anti-CD47 para mejorar la inmunización
|
|
WO2015041987A1
(en)
*
|
2013-09-18 |
2015-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of efferocytosis pathways for treatment of atherosclerotic disease
|
|
WO2015161267A2
(en)
|
2014-04-18 |
2015-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd99
|
|
ES2819451T3
(es)
|
2014-08-08 |
2021-04-16 |
Univ Leland Stanford Junior |
Agentes PD-1 de alta afinidad y procedimientos de uso
|
|
CN113621075B
(zh)
*
|
2014-08-08 |
2024-09-20 |
Alx肿瘤生物技术公司 |
SIRP-α变体构建体及其用途
|
|
WO2016023001A1
(en)
*
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
EP3188758B1
(en)
|
2014-08-08 |
2023-10-04 |
The Board of Trustees of the Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
|
LT3180363T
(lt)
|
2014-08-15 |
2019-11-25 |
Merck Patent Gmbh |
Sirp-alfa imunoglobulino sulieti baltymai
|
|
EP4257145B1
(en)
|
2014-08-26 |
2025-06-25 |
The Board of Trustees of the Leland Stanford Junior University |
Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
|
|
CA2958898A1
(en)
*
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
CA2959821C
(en)
|
2014-10-24 |
2024-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
US10864268B2
(en)
*
|
2014-11-18 |
2020-12-15 |
Janssen Pharmaceutica Nv |
CD47 antibodies, methods, and uses
|
|
EP3240569A4
(en)
*
|
2014-12-30 |
2018-05-30 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
|
EP3261671B1
(en)
|
2015-02-27 |
2020-10-21 |
The Board of Trustees of the Leland Stanford Junior University |
Combination therapy for treatment of atherosclerosis
|
|
CN106146670B
(zh)
*
|
2015-04-24 |
2019-01-15 |
宜明昂科生物医药技术（上海）有限公司 |
一种新的重组双功能融合蛋白及其制备和应用
|
|
WO2016179399A1
(en)
*
|
2015-05-06 |
2016-11-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity cd47 analogs
|
|
DK3298043T3
(da)
*
|
2015-05-18 |
2021-02-15 |
Ab Initio Biotherapeutics Inc |
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
|
|
IL294679B2
(en)
|
2015-08-07 |
2023-10-01 |
Alx Oncology Inc |
Structures with a SIRP-alpha site or its variant
|
|
BR102016018074A2
(pt)
*
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
|
ES2894335T5
(es)
|
2015-08-26 |
2024-06-27 |
Univ Leland Stanford Junior |
Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
|
|
CN115569192A
(zh)
|
2015-12-11 |
2023-01-06 |
小利兰·斯坦福大学托管委员会 |
以双重靶向cd47和egfr来治疗癌症
|
|
CN114716552B
(zh)
|
2016-01-11 |
2024-05-24 |
四十七公司 |
人源化、小鼠或嵌合抗cd47单克隆抗体
|
|
EP4438626A3
(en)
|
2016-04-14 |
2024-12-04 |
OSE Immunotherapeutics |
New anti-sirpa antibodies and their therapeutic applications
|
|
US11472878B2
(en)
|
2016-04-15 |
2022-10-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
|
|
US11649284B2
(en)
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
|
CA3019841A1
(en)
|
2016-04-29 |
2017-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
US10148939B2
(en)
|
2016-07-19 |
2018-12-04 |
Gopro, Inc. |
Mapping of spherical image data into rectangular faces for transport and decoding across networks
|
|
ES2987333T3
(es)
*
|
2016-10-26 |
2024-11-14 |
Univ Leland Stanford Junior |
Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación
|
|
WO2018081898A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
WO2018081897A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
EP3563835A4
(en)
*
|
2016-12-29 |
2020-12-30 |
Korea Institute of Science and Technology |
NEW EXOSOME-BASED ANTI-CANCER AGENT
|
|
DK3565579T3
(da)
|
2017-01-05 |
2023-09-04 |
Kahr Medical Ltd |
Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
|
WO2018127916A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
HRP20220230T1
(hr)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
|
|
CN110913875A
(zh)
|
2017-01-06 |
2020-03-24 |
同生运营公司 |
程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
|
|
WO2018140940A1
(en)
|
2017-01-30 |
2018-08-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
A non-genotoxic conditioning regimen for stem cell transplantation
|
|
US11286301B2
(en)
*
|
2017-02-28 |
2022-03-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antifibrotic activity of CD47 blockade
|
|
US11078272B2
(en)
|
2017-03-09 |
2021-08-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of CD47 pathway
|
|
CN117065013A
(zh)
|
2017-06-21 |
2023-11-17 |
小利兰·斯坦福大学托管委员会 |
针对血液恶性肿瘤的cd47靶向疗法的给药参数
|
|
WO2019014391A1
(en)
|
2017-07-12 |
2019-01-17 |
Synlogic Operating Company, Inc. |
MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS
|
|
AU2018312222B2
(en)
|
2017-08-02 |
2024-11-21 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
|
US11529425B2
(en)
|
2017-09-07 |
2022-12-20 |
Dingfu Biotarget Co., Ltd. |
Immunoconjugates comprising signal regulatory protein alpha
|
|
WO2019061012A1
(zh)
*
|
2017-09-26 |
2019-04-04 |
南京凯地生物科技有限公司 |
靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
|
|
WO2019073080A1
(en)
|
2017-10-13 |
2019-04-18 |
Ose Immunotherapeutics |
ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
|
|
CN111247172B
(zh)
|
2017-10-18 |
2023-11-14 |
四十七公司 |
基于抗cd47剂的卵巢癌疗法
|
|
CA3080640C
(en)
|
2017-11-06 |
2024-04-09 |
Trillium Therapeutics Inc. |
Cd47 blockade with radiation therapy
|
|
CA3083946A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Cd47 antibodies and uses thereof for treating cancer
|
|
WO2019109357A1
(zh)
*
|
2017-12-08 |
2019-06-13 |
杭州翰思生物医药有限公司 |
抗pd-1/cd47的双特异性抗体及其应用
|
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
|
EP4129336B1
(en)
|
2018-02-12 |
2025-05-07 |
Forty Seven, LLC |
Anti-cd47 agent-based treatment of cd20-positive cancer
|
|
CN108484774B
(zh)
*
|
2018-03-09 |
2021-11-05 |
上海高菲生物科技有限公司 |
一种SIRPα融合蛋白及其制备方法和用途
|
|
CN111936167A
(zh)
*
|
2018-03-13 |
2020-11-13 |
延龄草治疗公司 |
Egfr抗体对cd47阻断疗法的改善
|
|
KR20210006338A
(ko)
|
2018-03-13 |
2021-01-18 |
오제 이뮈노테라프틱스 |
항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
|
|
CN108872569A
(zh)
*
|
2018-06-19 |
2018-11-23 |
浠思（上海）生物技术有限公司 |
利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
|
|
BR112020023322A2
(pt)
|
2018-07-10 |
2021-02-02 |
National University Corporation Kobe University |
anticorpo anti-sirpalfa
|
|
SG11202013167UA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
|
|
CN112543767B
(zh)
|
2018-07-11 |
2024-05-31 |
卡尔医学有限公司 |
Pd1-4-1bbl变体融合蛋白及其使用方法
|
|
KR102129522B1
(ko)
*
|
2018-07-26 |
2020-07-02 |
한국과학기술연구원 |
암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물
|
|
JP2021534769A
(ja)
|
2018-08-31 |
2021-12-16 |
エーエルエックス オンコロジー インコーポレイテッド |
デコイポリペプチド
|
|
WO2020047651A1
(en)
|
2018-09-04 |
2020-03-12 |
Trillium Therapeutics Inc. |
Cd47 blockade with parp inhibition for disease treatment
|
|
CN109306017B
(zh)
*
|
2018-10-12 |
2021-02-09 |
倍而达药业（苏州）有限公司 |
一种基于SIRP-αD1突变体制备的重组蛋白及应用
|
|
BR112021008908A2
(pt)
*
|
2018-11-07 |
2021-08-17 |
Daiichi Sankyo Company, Limited |
método para melhorar a cinética do peptídeo no sangue
|
|
CN111303293B
(zh)
|
2018-11-14 |
2022-08-30 |
杭州尚健生物技术有限公司 |
一种融合蛋白及其用途
|
|
KR20210094609A
(ko)
|
2018-11-28 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
|
|
US20220289821A1
(en)
*
|
2018-11-29 |
2022-09-15 |
Trillium Therapeutics Inc |
Biomarkers for cd47 blockade therapy
|
|
EP3898676A1
(en)
|
2018-12-21 |
2021-10-27 |
OSE Immunotherapeutics |
Bifunctional anti-pd-1/sirpa molecule
|
|
JP7680032B2
(ja)
|
2019-03-18 |
2025-05-20 |
ラディック インスティテュート フォア キャンサー リサーチ リミテッド |
Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用
|
|
CN119700933A
(zh)
|
2019-05-31 |
2025-03-28 |
Alx肿瘤生物技术公司 |
用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
|
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2020257196A1
(en)
*
|
2019-06-17 |
2020-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating infections by blocking pathogen mimics of cd47
|
|
EP3999107A1
(en)
|
2019-07-16 |
2022-05-25 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
CN118178645A
(zh)
|
2019-10-18 |
2024-06-14 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
US20210147568A1
(en)
|
2019-10-31 |
2021-05-20 |
Forty Seven, Inc. |
Anti-cd47 based treatment of blood cancer
|
|
AU2020394204A1
(en)
|
2019-11-27 |
2022-06-02 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
US20230220342A1
(en)
*
|
2020-04-24 |
2023-07-13 |
Georgia State University Research Foundation, Inc. |
SIRPa Deficient Macrophages for Treating Cancer
|
|
JP2023528341A
(ja)
*
|
2020-06-01 |
2023-07-04 |
エーエルエックス オンコロジー インコーポレイテッド |
低メチル化剤を含むがんを治療するための併用療法
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
CN114057888A
(zh)
*
|
2020-07-30 |
2022-02-18 |
三生国健药业（上海）股份有限公司 |
一种SIRPα-Fc融合蛋白
|
|
JP7446953B2
(ja)
*
|
2020-08-27 |
2024-03-11 |
株式会社三共 |
遊技機
|
|
KR102557016B1
(ko)
*
|
2020-09-22 |
2023-07-20 |
비피진 주식회사 |
암 치료를 위한 cd47 바인더 및 리포좀 복합체
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
US20220305100A1
(en)
|
2021-03-12 |
2022-09-29 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
EP4329520A1
(en)
|
2021-04-27 |
2024-03-06 |
Pfizer Inc. |
Enhancement of cd47 blockade therapy with dhfr inhibitors
|
|
AU2022273727A1
(en)
|
2021-05-13 |
2023-11-09 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222595A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2023003331A1
(en)
*
|
2021-07-19 |
2023-01-26 |
Yuhan Corporation |
Sirp-alpha variants and use thereof
|
|
KR20240091056A
(ko)
|
2021-10-28 |
2024-06-21 |
길리애드 사이언시즈, 인코포레이티드 |
피리디진-3(2h)-온 유도체
|
|
US20250235504A1
(en)
|
2021-10-29 |
2025-07-24 |
Pfizer Inc. |
Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
|
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN118139874A
(zh)
*
|
2021-11-01 |
2024-06-04 |
山东先声生物制药有限公司 |
SIRPa突变体及其应用
|
|
WO2023079438A1
(en)
|
2021-11-08 |
2023-05-11 |
Pfizer Inc. |
Enhancement of cd47 blockade therapy with anti-vegf agents
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
KR20240117080A
(ko)
*
|
2021-12-21 |
2024-07-31 |
에프비디 바이올로직스 리미티드 |
조작된 SIRPα 변이체 및 이의 사용 방법
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024545193A
(ja)
|
2021-12-22 |
2024-12-05 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
US20250051441A1
(en)
*
|
2021-12-23 |
2025-02-13 |
Fbd Biologics Limited |
Cd47/4-1bb-targeting protein complex and methods of use thereof
|
|
IL314210A
(en)
*
|
2022-01-18 |
2024-09-01 |
Fbd Biologics Ltd |
CD47/PD-L1-targeted protein complex and methods of using it
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
US12358887B2
(en)
|
2022-03-17 |
2025-07-15 |
Gilead Sciences, Inc. |
IKAROS Zinc Finger Family degraders and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
IL315706A
(en)
|
2022-03-24 |
2024-11-01 |
Bitterroot Bio Inc |
Sirp-alpha fusion polypeptides with modified fc domains
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
US20250257113A1
(en)
*
|
2022-03-24 |
2025-08-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multivalent sirp-alpha fusion polypeptides
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN119487038A
(zh)
|
2022-04-21 |
2025-02-18 |
吉利德科学公司 |
Kras g12d调节化合物
|
|
AU2023263628A1
(en)
*
|
2022-05-06 |
2024-12-19 |
Biosion Inc. |
Recombinant fusion protein targeting cd40 and cd47
|
|
WO2023228044A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Dosing regimens of sirp alpha fusion proteins for treatment of cancer
|
|
JP2025523369A
(ja)
|
2022-06-01 |
2025-07-23 |
エーエルエックス オンコロジー インコーポレイテッド |
尿路上皮癌腫を治療するための併用療法
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
WO2024015634A2
(en)
*
|
2022-07-15 |
2024-01-18 |
Nutcracker Therapeutics, Inc. |
Mrna therapies including sirp-alpha
|
|
WO2024040151A1
(en)
|
2022-08-18 |
2024-02-22 |
Pfizer Inc. |
Sirp alpha fusion protein and anti-cd38 antibody combination therapies
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4630121A1
(en)
|
2022-12-09 |
2025-10-15 |
Pfizer Inc. |
Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
|
|
TW202440151A
(zh)
|
2022-12-09 |
2024-10-16 |
美商輝瑞大藥廠 |
Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024193635A1
(en)
*
|
2023-03-22 |
2024-09-26 |
Wangzhi LI |
Sirp variants and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
TW202511298A
(zh)
*
|
2023-05-31 |
2025-03-16 |
香港商Ｆｂｄ生物製劑有限公司 |
靶向ｃｄ４７／ｐｄ—ｌ１之蛋白質複合物及其使用方法
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|